Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 YearsThe Motley Fool • 06/12/23
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall StreetThe Motley Fool • 05/30/23
Top 1% Biotech Viking Therapeutics Backs Off Its Record Run On NASH EnthusiasmInvestors Business Daily • 05/16/23
Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record HighInvestors Business Daily • 05/16/23
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)PRNewsWire • 05/16/23
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move TodayThe Motley Fool • 05/01/23